Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Blood (2024) 143 (25): 2588–2598.

https://doi.org/10.1182/blood.2023022564

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

Gut Microbiome Links to Disease Stage and Immune Microenvironment in Patients with Chronic Lymphocytic Leukemia

Tereza Faitova, Caspar Da Cunha-Bang, Hans Jakob Hartling, Jakob Thaning Bay, Hanne Vibeke Marquart, Arnon P. Kater, Mark-David Levin, Sabina Kersting, Carsten Utoft Niemann, Rebecka Svanberg

Blood (2023) 142 (Supplement 1): 6515.

https://doi.org/10.1182/blood-2023-186158

Published: 2023

Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater

Blood (2023) 142 (5): 446–459.

https://doi.org/10.1182/blood.2023019634

Published: 2023

Includes: Supplemental data

Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Blood (2022) 140 (Supplement 1): 842–845.

https://doi.org/10.1182/blood-2022-164786

Published: 2022

Journal Articles

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Blood (2022) 140 (Supplement 1): 839–841.

https://doi.org/10.1182/blood-2022-163775

Published: 2022

Journal Articles

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

Carsten U. Niemann, Caspar da Cunha-Bang, Marie Helleberg, Sisse R. Ostrowski, Christian Brieghel

Blood (2022) 140 (5): 445–450.

https://doi.org/10.1182/blood.2022016147

Published: 2022

Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 72.

https://doi.org/10.1182/blood-2021-147729

Published: 2021

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 2639.

https://doi.org/10.1182/blood-2021-147790

Published: 2021

Journal Articles

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Caspar Da Cunha-Bang, MD PhD, Rudy Agius, Arnon P. Kater, Mark-David Levin, MD PhD, Anders Österborg, MD PhD, Mattias Mattsson, MD, Carsten Utoft Niemann, MD PhD

Blood (2019) 134 (Supplement_1): 4304.

https://doi.org/10.1182/blood-2019-121907

Published: 2019

Journal Articles

Mapping Comorbidity in CLL: Impact on Prognostic Factors, Treatment Patterns and Causes of Death

Emelie Curovic Rotbain, MD, Carsten Utoft Niemann, MD PhD Ass. Prof, Klaus Rostgaard, MSc., Caspar Da Cunha-Bang, MD PhD, Henrik Hjalgrim, MD Dr.MD, Henrik Frederiksen, MD Prof

Blood (2019) 134 (Supplement_1): 4285.

https://doi.org/10.1182/blood-2019-122673

Published: 2019

Journal Articles

Risk Factors Associated with Richter's Transformation in Patients with Chronic Lymphocytic Leukemia

Yasmin Ben-Dali, Mariam Hussein Hleuhel, MDcal student, Michael Asger Andersen, MD, Christian Brieghel, Erik Clasen-Linde, MD, Caspar Da Cunha-Bang, MD PhD, Carsten Utoft Niemann

Blood (2018) 132 (Supplement 1): 1697.

https://doi.org/10.1182/blood-2018-99-112442

Published: 2018

Journal Articles

Bacterial Infections in Patients with Chronic Lymphocytic Leukemia: A Longitudinal Nation-Wide Study

Michael Asger Andersen, MD, Caspar Da Cunha-Bang, MD PhD, Marie Helleberg, MD PhD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 3461.

https://doi.org/10.1182/blood.V130.Suppl_1.3461.3461

Published: 2017

Journal Articles

IGHV Mutation Status and Outcome in CLL Patients Treated with Chemoimmunotherapy: A Nationwide Analysis

Emelie Curovic Curovic Rotbain, MD, Caspar Da Cunha-Bang, MD PhD, Henrik Hjalgrim, Klaus Rostgaard, MSc., Michael A Andersen, MD, Carsten Utoft Niemann, MD PhD, Henrik Frederiksen, associate professor, consultant, PhD

Blood (2017) 130 (Supplement 1): 1742.

https://doi.org/10.1182/blood.V130.Suppl_1.1742.1742

Published: 2017

Journal Articles

Prognostic Impact of Subclonal TP53 Aberrations in Chronic Lymphocytic Leukemia Validated By a Robust Targeted Next Generation Sequencing Assay

Christian Brieghel, MD, Christina Westmose Yde, MSc, PhD, Caspar da Cunha-Bang, MD PhD, Savvas Kinalis, Data scientist, Lone Bredo Pedersen, Lars Jønson, MSc, PhD, Finn Cilius Nielsen, MD PhD, Carsten Utoft Niemann

Blood (2016) 128 (22): 4380.

https://doi.org/10.1182/blood.V128.22.4380.4380

Published: 2016

Journal Articles

Increased Risk of Second Hematological and Non-Hematological Malignancies in CLL Patients Treated with Chemotherapy As Compared to Untreated Patients and Matched Controls - Results from a Danish Population Based Study

Caspar Da Cunha-Bang, Klaus Rostgaard, Jacob Simonsen, Christian H Geisler, Henrik Hjalgrim, Henrik Frederiksen, MD PhD, Kirsten Grønbæk, Carsten Utoft Niemann

Blood (2016) 128 (22): 3219.

https://doi.org/10.1182/blood.V128.22.3219.3219

Published: 2016

Journal Articles

The CLL-IPI applied in a population-based cohort

Caspar da Cunha-Bang, Ilse Christiansen, Carsten Utoft Niemann

Blood (2016) 128 (17): 2181–2183.

https://doi.org/10.1182/blood-2016-07-724740

Published: 2016

Journal Articles

Improved Survival for Patients with CLL in the Era of Combination Chemoimmunotherapy - a Danish Population Based Study

Caspar da Cunha-Bang, Jacob Simonsen, Klaus Rostgaard, Christian H Geisler, Henrik Hjalgrim, Carsten Niemann

Blood (2015) 126 (23): 1740.

https://doi.org/10.1182/blood.V126.23.1740.1740

Published: 2015

NARROW

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Gut Microbiome Links to Disease Stage and Immune Microenvironment in Patients with Chronic Lymphocytic Leukemia

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Mapping Comorbidity in CLL: Impact on Prognostic Factors, Treatment Patterns and Causes of Death

Risk Factors Associated with Richter's Transformation in Patients with Chronic Lymphocytic Leukemia

Bacterial Infections in Patients with Chronic Lymphocytic Leukemia: A Longitudinal Nation-Wide Study

IGHV Mutation Status and Outcome in CLL Patients Treated with Chemoimmunotherapy: A Nationwide Analysis

Prognostic Impact of Subclonal TP53 Aberrations in Chronic Lymphocytic Leukemia Validated By a Robust Targeted Next Generation Sequencing Assay

Increased Risk of Second Hematological and Non-Hematological Malignancies in CLL Patients Treated with Chemotherapy As Compared to Untreated Patients and Matched Controls - Results from a Danish Population Based Study

The CLL-IPI applied in a population-based cohort

Improved Survival for Patients with CLL in the Era of Combination Chemoimmunotherapy - a Danish Population Based Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only